PL2094684T3 - 1,5-difenylo-3-benzyloamino-1,5-dihydropirolidyn-2-ony jako modulatory receptora CB1 - Google Patents

1,5-difenylo-3-benzyloamino-1,5-dihydropirolidyn-2-ony jako modulatory receptora CB1

Info

Publication number
PL2094684T3
PL2094684T3 PL07871197T PL07871197T PL2094684T3 PL 2094684 T3 PL2094684 T3 PL 2094684T3 PL 07871197 T PL07871197 T PL 07871197T PL 07871197 T PL07871197 T PL 07871197T PL 2094684 T3 PL2094684 T3 PL 2094684T3
Authority
PL
Poland
Prior art keywords
dihydropyrrolidin
benzylamino
diphenyl
ones
receptor modulators
Prior art date
Application number
PL07871197T
Other languages
English (en)
Inventor
David Scott Coffey
Jingdan Hu
Stacy Jo Keding
Joseph Herman Junior Krushinski
John Mehnert Schaus
David Edward Tupper
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL2094684T3 publication Critical patent/PL2094684T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL07871197T 2006-10-23 2007-10-22 1,5-difenylo-3-benzyloamino-1,5-dihydropirolidyn-2-ony jako modulatory receptora CB1 PL2094684T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86254006P 2006-10-23 2006-10-23
PCT/US2007/082042 WO2008070306A2 (en) 2006-10-23 2007-10-22 1,5-diphenyl-3-benzylamin0-1,5-dihydr0pyrr0lidin-2-0ne as cb1 receptor modulators
EP07871197A EP2094684B1 (en) 2006-10-23 2007-10-22 1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidin 2-ones as cb1 receptor modulators

Publications (1)

Publication Number Publication Date
PL2094684T3 true PL2094684T3 (pl) 2011-05-31

Family

ID=39386481

Family Applications (2)

Application Number Title Priority Date Filing Date
PL07871196T PL2099784T3 (pl) 2006-10-23 2007-10-22 1,5-difenylo-3-pirydynyloamino-1,5-dihydrioirrolidyn-2-ony jako modulatory receptora cb1
PL07871197T PL2094684T3 (pl) 2006-10-23 2007-10-22 1,5-difenylo-3-benzyloamino-1,5-dihydropirolidyn-2-ony jako modulatory receptora CB1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL07871196T PL2099784T3 (pl) 2006-10-23 2007-10-22 1,5-difenylo-3-pirydynyloamino-1,5-dihydrioirrolidyn-2-ony jako modulatory receptora cb1

Country Status (23)

Country Link
US (2) US7998985B2 (pl)
EP (2) EP2099784B1 (pl)
JP (2) JP5331002B2 (pl)
KR (2) KR101088229B1 (pl)
CN (2) CN101528733B (pl)
AR (1) AR063497A1 (pl)
AT (1) ATE492543T1 (pl)
AU (1) AU2007329808B2 (pl)
BR (1) BRPI0717347A2 (pl)
CA (2) CA2667372C (pl)
CL (1) CL2007003002A1 (pl)
CY (1) CY1111140T1 (pl)
DE (1) DE602007011495D1 (pl)
DK (2) DK2099784T3 (pl)
EA (2) EA015175B1 (pl)
ES (2) ES2356025T3 (pl)
MX (2) MX2009004054A (pl)
PE (1) PE20080926A1 (pl)
PL (2) PL2099784T3 (pl)
PT (2) PT2099784E (pl)
SI (2) SI2099784T1 (pl)
TW (1) TW200825067A (pl)
WO (2) WO2008070306A2 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080926A1 (es) * 2006-10-23 2008-07-19 Lilly Co Eli Compuestos cb1
EA201071222A1 (ru) * 2008-04-22 2011-12-30 Эли Лилли Энд Компани Соединения 1,5-дифенилпирролидин-2-она в качестве лигандов cb-1
PL2280961T3 (pl) 2008-04-22 2012-12-31 Lilly Co Eli Związki 1,5-difenylo-pirolidyn-2-onu jako ligandy CB-1
US20110280813A1 (en) * 2008-11-13 2011-11-17 Alice Prince Neuraminidase inhibitors and uses thereof
DE112011102349T5 (de) * 2010-07-15 2013-04-18 Oleg Iliich Epshtein Pharmazeutische Zusammensetzung und Behandlungsverfahren
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2022132803A1 (en) * 2020-12-14 2022-06-23 The Board Of Trustees Of The Leland Stanford Junior University Cb2 receptor agonists
WO2023205180A1 (en) 2022-04-19 2023-10-26 Nurix Therapeutics, Inc. Biomarkers for cbl, and compositions and methods for their use
US20230414598A1 (en) 2022-06-22 2023-12-28 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds and antiemetic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533657A (en) 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
KR20060131908A (ko) * 2004-02-19 2006-12-20 솔베이 파마슈티칼스 비. 브이 Ｃｂ1-길항 활성을 갖는 이미다졸린 유도체
US20060035245A1 (en) * 2004-04-20 2006-02-16 Ason Brandon L Modulators of enzymatic nucleic acid elements mobilization
WO2007020502A2 (en) * 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Cannabinoid receptor ligands and uses thereof
PE20080926A1 (es) * 2006-10-23 2008-07-19 Lilly Co Eli Compuestos cb1

Also Published As

Publication number Publication date
ES2356025T3 (es) 2011-04-04
EP2094684A2 (en) 2009-09-02
ATE492543T1 (de) 2011-01-15
JP2010507590A (ja) 2010-03-11
DK2094684T3 (da) 2011-03-14
EP2094684B1 (en) 2010-12-22
PL2099784T3 (pl) 2013-05-31
DK2099784T3 (da) 2013-01-14
WO2008070305A2 (en) 2008-06-12
TW200825067A (en) 2008-06-16
KR101088229B1 (ko) 2011-11-30
US7998985B2 (en) 2011-08-16
KR101088236B1 (ko) 2011-11-30
JP5331001B2 (ja) 2013-10-30
CA2667372A1 (en) 2008-06-12
PT2099784E (pt) 2013-01-04
SI2099784T1 (sl) 2013-02-28
AR063497A1 (es) 2009-01-28
CN101528733A (zh) 2009-09-09
PE20080926A1 (es) 2008-07-19
WO2008070305A3 (en) 2008-08-28
MX2009004054A (es) 2009-04-27
KR20090069316A (ko) 2009-06-30
PT2094684E (pt) 2011-01-28
US20100016375A1 (en) 2010-01-21
KR20090071613A (ko) 2009-07-01
EP2099784B1 (en) 2012-12-12
CN101528733B (zh) 2013-10-16
CA2667372C (en) 2013-09-03
WO2008070306A2 (en) 2008-06-12
JP2010507589A (ja) 2010-03-11
CL2007003002A1 (es) 2008-06-06
AU2007329807A1 (en) 2008-06-12
EP2099784A2 (en) 2009-09-16
CA2667210A1 (en) 2008-06-12
EA200970404A1 (ru) 2009-10-30
WO2008070306A3 (en) 2008-07-31
AU2007329808A1 (en) 2008-06-12
CN101528732A (zh) 2009-09-09
DE602007011495D1 (de) 2011-02-03
US8168659B2 (en) 2012-05-01
MX2009004053A (es) 2009-04-27
EA015175B1 (ru) 2011-06-30
EA015745B1 (ru) 2011-10-31
BRPI0717347A2 (pt) 2014-01-14
US20090275618A1 (en) 2009-11-05
JP5331002B2 (ja) 2013-10-30
CA2667210C (en) 2013-09-24
AU2007329808B2 (en) 2013-11-07
SI2094684T1 (sl) 2011-04-29
ES2398388T3 (es) 2013-03-15
CY1111140T1 (el) 2015-06-11
EA200970405A1 (ru) 2009-12-30
CN101528732B (zh) 2013-04-03

Similar Documents

Publication Publication Date Title
IL198990A0 (en) Cb1 receptor modulators
GB0623101D0 (en) Secure network architecture
IL201973A0 (en) 3,3-spiroindolinone derivatives
IL225694A0 (en) Compounds 6,5- dihydro-h1-pyridine-2-one
ZA201001797B (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
IL191767A0 (en) Imidazoles as gaba-b receptor modulators
PL2094684T3 (pl) 1,5-difenylo-3-benzyloamino-1,5-dihydropirolidyn-2-ony jako modulatory receptora CB1
GB0701992D0 (en) Grehlin Receptor Modulators
SI2356123T1 (sl) Piro-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo(e)azuleni
ZA201004828B (en) Cannabinoid receptor modulators
IL188388A0 (en) Pyrazole derivatives as cb1 modulators
AU2008207290A8 (en) Stirrup
GB0616467D0 (en) Network tunnelling
GB0622569D0 (en) Cannabinoid receptor modulators
ZA200806237B (en) Cannibinoid receptor modulators
IL194972A0 (en) 2-alkoxy-3,4,5-trihydroxy-alkylamide-
GB0811212D0 (en) CB1 Receptor Modulators
ZA200904663B (en) CB1 receptor modulators
DE602006020489D1 (de) Cb1-rezeptormodulatoren
GB0719111D0 (en) T.m.2
GB0724096D0 (en) Cannabinoid receptor modulators
HK1122811A (en) Cannibinoid receptor modulators
GB0623853D0 (en) Receptor
GB0608516D0 (en) Receptor
GB0623399D0 (en) Receptor